- Cite This Article as
- Corresponding Author
Objective: Angiotensive receptor blockers (ARBs) are very potent antihypertensive agents , Telmisartan being the prototype and most widely used.This study was undertaken to compare the efficacy and safety of Azilsartan a new ARB with Telmisartan. Material and methods : This prospective study was carried out in patients attending the Department of Medicine, SCB Medical college, Cuttack. Patients with newly diagnosed with stage I-II essential hypertension of either sex within the age group of 18?65 years with blood pressure of ≥140/90 mmHg were included in the study. Severe hypertension >180/110 mm of Hg, hypersensitivity to ARBs, secondary hypertension with any other etiology, pregnant women, history of Drug/ Alcohol abuse, cardiac arrhythmias were excluded. Patients who gave consent for the study were divided into 2 random groups 1 and 2 ? the first received azilsartan and the second received telmisartan. Point of control was defined as blood pressure<140/90 mm of Hg after initiation of therapy. Results : 180 patients were randomized into two groups. Out of 90 patients included in group 1 who received azilsartan, 4 lost for follow up. Out of 90 patients included in group 2 who received telmisartan, 5 lost for follow up. There was no significant difference between the two drugs in both mean systolic and diastolic blood pressure at 24hrs, 1 month and 3 months and 6 months. Mean diastolic blood pressure at 24 hrs was reduced more with telmisartan compared to azilsartan which is significant. Hypotension related adverse effects occurred in 3% of the patients in azilsartan group while it occurred in 8% of them in telmisartan group. Conclusion: Azilsartan is an effective blood pressure lowering drug with its safety and efficacy comparable to that of telmisartan.
- Whalen Karen, Richard Finkel, and Thomas A. Panavelil. Lippincots illustrated reviews: Pharmacology. Sixth edition. Philadelphia: Wolters Kluwer, 2015 pg. no:225.
- Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305?1315.
- Turnbull F, for the Blood Pressure Lowering Treatment Trialists? Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003;362:1527?1535.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High BP. Hypertension. 2003; 42:1206?1252.
- European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003; 21:1011?1054.
- Schmidt-Ott K. M., Kagiyama S., Phillips M. I. The multiple actions of angiotensin II in atherosclerosis. Regul. Pept. 2000;93, 65?77.
- Olivares-Reyes J. A., Arellano-Plancarte A., Castillo- Hernandez J. R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell. Endocrinol. 2009;302:128?139.
- Bertram G Katzung, Anthony J Trevor Katzung, Basic and Clinical Pharmacology 13th Edition, 2015, page
- Takeda Pharmaceuticals North America. Edarbi prescribing information. 2011.
- Kohara Y, Imamiya E, Kubo K, Wada T, Inada Y, Naka T. A new class of angiotensin II receptor antagonists with a novel acidic bioisostere. Bioorganic Medicinal Chemistry Letters. 1995;5:1903-8.
- Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. 1996;39:5228-35.
- Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade III essential hypertension: a randomized, double-blind clinical study. Hypertens Res.; 2012.
- Naka T, Kubo K. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Curr Pharm Des. 1999;5:453-72.
- Baker WL, White WB. Azilsartan medoxomil: A new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother. 2011;45:150615.
- Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists? Collaboration. Effects of ace inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists? collaboration. Lancet. 2000;356:1955-64.
- Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21:181-90.
- Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. The Journal of Clinical Hypertension. 2011;13:467-72.
- White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-20.
[Lenka D.N. and Routray S.N. (2019); EFFICACY AND SAFETY OF AZILSARTAN COMPARED WITH TELMISARTAN IN HYPERTENSIVE PATIENTS. Int. J. of Adv. Res. 7 (7). 143-149] (ISSN 2320-5407). www.journalijar.com
PROFESSOR, CARDIOLOGY. S C B MEDICAL COLLEGE ,CUTTACK,ODISHA. INDIA
Article DOI: 10.21474/IJAR01/9337 DOI URL: http://dx.doi.org/10.21474/IJAR01/9337
Share this article
This work is licensed under a Creative Commons Attribution 4.0 International License.